Section Arrow
NSRX.NYSE-M
- Nasus Pharma Ltd.
Quotes are at least 15-min delayed:2026/03/10 03:21 EDT
Regular Hours
Last
 4.11
-0.75 (-15.43%)
Day High 
4.11 
Prev. Close
4.86 
1-M High
6.47 
Volume 
4.46K 
Bid
--
Ask
--
Day Low
4.11 
Open
4.11 
1-M Low
3.99 
Market Cap 
57.13M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.95 
20-SMA 5.26 
50-SMA 6.19 
52-W High 9.9899 
52-W Low 3.99 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.21/--
Enterprise Value
57.13M
Balance Sheet
Book Value Per Share
-0.37
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MDCXMedicus Pharma Ltd0.52+0.1348+34.99%-- 
PFEPfizer26.81-0.24-0.89%19.84PE
NVONovo-Nordisk A/S39.78+1.2+3.11%10.75PE
BMYBristol-Myers Squibb Co60.63+0.34+0.56%17.41PE
MRKMerck & Co117.11+1.32+1.14%15.9PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.